Novo Nordisk A/S ADR
(NVO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Sales | 19,448,130 | 18,290,950 | 17,098,960 | 16,966,620 | 16,610,510 |
| Cost of Goods | 3,206,782 | 3,011,191 | 2,693,639 | 2,678,301 | 2,553,394 |
| Gross Profit | 16,241,340 | 15,279,760 | 14,405,320 | 14,288,320 | 14,057,110 |
| Operating Expenses | 7,950,020 | 7,412,750 | 7,181,741 | 6,850,535 | 6,860,513 |
| Operating Income | 8,292,104 | 7,867,202 | 7,224,219 | 7,438,087 | 7,196,995 |
| Interest Expense | 401,997 | 598,851 | 268,340 | 232,863 | 107,884 |
| Other Income | 249,409 | 9,744 | 324,454 | 189,268 | 13,672 |
| Pre-tax Income | 8,139,516 | 7,278,095 | 7,280,333 | 7,394,492 | 7,102,783 |
| Income Tax | 1,683,974 | 1,439,340 | 1,374,112 | 1,602,545 | 1,467,128 |
| Net Income Continuous | 6,455,542 | 5,838,755 | 5,906,221 | 5,791,947 | 5,635,655 |
| Net Income | $6,455,542 | $5,838,755 | $5,906,221 | $5,791,947 | $5,635,655 |
| EPS Basic Total Ops | 1.38 | 1.23 | 1.22 | 1.17 | 1.11 |
| EPS Basic Continuous Ops | 1.38 | 1.23 | 1.22 | 1.17 | 1.11 |
| EPS Diluted Total Ops | 1.38 | 1.23 | 1.22 | 1.17 | 1.11 |
| EPS Diluted Continuous Ops | 1.38 | 1.23 | 1.22 | 1.17 | 1.11 |
| EPS Diluted Before Non-Recurring Items | 1.38 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $9,173,462 | $8,715,786 | $7,824,350 | $7,921,434 | $7,671,475 |